Rothschild & Co Redburn Increases Gilead Sciences (NASDAQ:GILD) Price Target to $159.00

Gilead Sciences (NASDAQ:GILD) had its target price hoisted by analysts at Rothschild & Co Redburn from $153.00 to $159.00 in a research note issued to investors on Tuesday,MarketScreener reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Rothschild & Co Redburn’s price objective points to a potential upside of 23.15% from the stock’s current price.

A number of other analysts have also commented on GILD. Scotiabank started coverage on shares of Gilead Sciences in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $140.00 price target for the company. Argus lifted their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $110.00 to $115.00 and gave the company a “neutral” rating in a research note on Thursday, January 8th. Morgan Stanley dropped their price target on Gilead Sciences from $151.00 to $150.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 13th. Finally, Wells Fargo & Company lifted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, December 10th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has an average rating of “Moderate Buy” and an average target price of $133.52.

Gilead Sciences Trading Up 4.0%

Shares of NASDAQ:GILD opened at $129.11 on Tuesday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. Gilead Sciences has a 1 year low of $91.84 and a 1 year high of $129.39. The company has a market cap of $160.18 billion, a P/E ratio of 20.02, a PEG ratio of 0.65 and a beta of 0.33. The stock’s fifty day moving average price is $123.64 and its 200-day moving average price is $118.37.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the company earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Sell-side analysts expect that Gilead Sciences will post 7.95 earnings per share for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $124.31, for a total value of $372,930.00. Following the completion of the sale, the insider owned 103,221 shares in the company, valued at $12,831,402.51. This represents a 2.82% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $123.50, for a total value of $617,500.00. Following the transaction, the director directly owned 8,920 shares in the company, valued at approximately $1,101,620. The trade was a 35.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 141,757 shares of company stock valued at $17,569,112 in the last ninety days. 0.27% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Gilead Sciences

Several large investors have recently added to or reduced their stakes in GILD. GoalVest Advisory LLC raised its position in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Corundum Trust Company INC purchased a new stake in Gilead Sciences in the 3rd quarter worth $26,000. Harbor Asset Planning Inc. bought a new stake in Gilead Sciences during the second quarter valued at about $27,000. Putney Financial Group LLC lifted its position in shares of Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares in the last quarter. Finally, Howard Hughes Medical Institute bought a new position in shares of Gilead Sciences in the second quarter worth about $30,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT-04/KEYNOTE-D19 results showing Trodelvy® (sacituzumab govitecan) + Keytruda® met the primary endpoint with a 35% PFS improvement (HR 0.65), supporting the combination as a potential new first-line standard in PD-L1+ metastatic TNBC — a meaningful commercial upside for Gilead’s Trodelvy franchise. New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results
• Positive Sentiment: Rothschild & Co Redburn raised its GILD price target to $159 and kept a “buy” rating, signaling institutional confidence and providing upside thesis support to momentum traders and fundamental buyers. Rothschild & Co Redburn Adjusts Price Target on Gilead Sciences
• Positive Sentiment: Investor commentary highlights margin expansion and stronger free cash flow as underappreciated drivers for Gilead’s valuation, supporting buy-side interest beyond the clinical story. Gilead Sciences: Margin Expansion And Cash Flow Strength Underpriced
• Neutral Sentiment: Market commentary includes a valuation check after recent share-price softness — useful context for investors assessing whether the recent run is a buy-the-news move or a reset toward fair value. Gilead Sciences (GILD) Valuation Check After Recent Share Price Softness
• Neutral Sentiment: Technical/relative-strength pieces note improved momentum in GILD, which can attract momentum traders but doesn’t change fundamentals by itself. Stocks generating improved relative strength: Gilead Sciences
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at $123.50) and reduced his stake by ~35.9% — an insider sale that may prompt investor questions about timing or tax/liquidity motives. SEC Filing — Form 4
• Negative Sentiment: RBC raised its target slightly to $103 but kept a “sector perform” rating — that target sits well below current levels and represents a cautious analyst view that could cap upside if other brokers follow suit. RBC Lifts Price Target on Gilead Sciences to $103

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.